Trending

– Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia’s Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference -TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ — Abe Yoando Pharma Co., Ltd., a nearly 300-year-old pharmaceutical…

Ribbon-cutting held on World Suicide Prevention DayRED BANK, N.J., Sept. 12, 2026 /PRNewswire/ — Red Bank Catholic High School officially opened a new Wellness Room on its Broad Street campus today, with a ribbon-cutting and blessing ceremony marking…

First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpoxDelivers integrated process development, regulatory…

Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the…

WASHINGTON, Aug. 22, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural…

HONG KONG, Aug. 21, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of…

VADUZ, Liechtenstein, Aug. 20, 2026 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA)…

Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or 177Lu) to support the…

LUND, Sweden, Aug. 18, 2026 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the…

GENEVA, Aug. 12, 2026 /PRNewswire/ — MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to…